TerrAscend (TSNDF) Other Non-Current Liabilities (2020 - 2026)
TerrAscend (TSNDF) posted quarterly Other Non-Current Liabilities of $1.7 million for Q1 2026, up 289.91% year-over-year from $446000.0 in Q1 2025, and down 45.45% quarter-over-quarter from $3.2 million in Q4 2025.
TerrAscend (TSNDF) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Other Non-Current Liabilities for 7 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 289.91% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 289.91% YoY), while the FY2025 annual figure was $3.2 million, up 606.87% from the prior year.
- Other Non-Current Liabilities eased to $1.7 million in Q1 2026 per TSNDF's latest filing, from $3.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $15.8 million in Q1 2023 and bottomed at $86000.0 in Q3 2025.
- Historically, Other Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $2.1 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 1065.83% — and 2025, when it plunged 95.02%.
- TerrAscend's Other Non-Current Liabilities stood at $711000.0 in 2022, then jumped by 626.02% to $5.2 million in 2023, then plunged by 91.26% to $451000.0 in 2024, then jumped by 606.87% to $3.2 million in 2025, then slumped by 45.45% to $1.7 million in 2026.
- Business Quant data shows TSNDF's Other Non-Current Liabilities at $1.7 million in Q1 2026, $3.2 million in Q4 2025, and $86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.69 Mn |
| Mar 31, 2026 | 1.74 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 178,000.00 |
| Mar 31, 2025 | 446,000.00 |
| Dec 31, 2024 | 451,000.00 |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 6.08 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | 15.84 Mn |
| Dec 31, 2022 | 711,000.00 |
| Sep 30, 2022 | 679,000.00 |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 2.55 Mn |
| Dec 31, 2020 | 132.26 Mn |